Adeka (TSE:4401) Raised Guidance And Dividends, Is The Discount Still Warranted?

Stronger guidance and higher dividends put Adeka in focus

Adeka (TSE:4401) raised its earnings and dividend forecasts on 7 August 2026, citing firm demand in its Chemicals business. Investors now have fresh information on profit expectations and shareholder payouts.

See our latest analysis for Adeka.

Adeka’s raised guidance comes after a mixed price pattern, with the share price declining 3.86% over the last day and 5.51% over the past week, yet still posting a 12.13% 1 month share price return and a 42.25% 1 year total shareholder return. This suggests momentum has cooled recently, while longer term returns remain strong.

If AI related demand in chemicals has your attention, this may be a useful moment to broaden your watchlist and review the 56 AI infrastructure stocks

Adeka now trades at a discount to both analyst targets and an estimate of fair value following a strong run and fresh guidance. Is that a sensible margin of safety, or a signal that the market sees real risks ahead?

Most Popular Narrative: 3% Undervalued

The most followed valuation narrative puts Adeka’s fair value at ¥4,648, slightly above the last close of ¥4,511. This points to a modest gap that investors are now weighing against the stronger guidance and higher dividends.

ADEKA is expecting a gradual recovery in demand for semiconductors in the second and third quarters, driven by robust investments in AI-related fields and a partial recovery in semiconductor demand. This is likely to contribute to increased sales in advanced semiconductor materials, positively impacting revenue and operating profit.

Read the complete narrative.

Want to see what sits behind that semiconductor push and the fair value gap? Revenue, margins, and earnings are all aligned in one integrated forecast story.

Result: Fair Value of ¥4,648 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Adeka’s story still carries real execution risk, particularly if Life Science demand stays weak or if currency swings and competitive pricing pressure margins more than expected.

Find out about the key risks to this Adeka narrative.

Next Steps

The sentiment around Adeka is cautiously positive, but the decision is yours and time matters if guidance or risk views change quickly. To see what is driving optimism in the data and judge whether it fits your own thesis, review the 4 key rewards

Looking for more investment ideas beyond Adeka?

If Adeka has sharpened your focus on what matters, do not stop here. Broaden your opportunity set now so you are not reacting after the move.

• Spot potential value early by reviewing the screener containing 70 high quality undiscovered gems that may not yet be crowded trades.
• Prioritise resilience by scanning the 55 resilient stocks with low risk scores if capital preservation is high on your list.
• Target dependable cash generation by checking the 38 dividend fortresses that could support consistent income.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com